Investment Thesis
Edwards Lifesciences demonstrates exceptional fundamental strength with best-in-class profitability (78% gross margin, 20.8% operating margin) and fortress-like balance sheet (0.06x debt/equity, 3.72x current ratio). The company generates substantial free cash flow ($1.3B, 22% FCF margin) with minimal leverage, positioning it as a low-risk, high-quality compounder in the medical devices sector.
EW Strengths
- Industry-leading gross margin of 78% indicates strong pricing power and operational efficiency
- Exceptional balance sheet health with 0.06x debt/equity ratio and $2.9B cash providing substantial financial flexibility
- Robust free cash flow generation of $1.3B with 22% FCF margin demonstrates sustainable earnings quality
- Strong interest coverage of 71.8x and liquidity ratios (3.72x current, 3.09x quick) indicate zero financial distress risk
- Consistent profitability with 17.7% net margin across challenging medical device environment
EW Risks
- Extreme YoY revenue growth of 29,843% appears anomalous and warrants investigation into one-time items or accounting changes affecting comparability
- EPS diluted down 73.7% YoY despite net income near-flat suggests significant share dilution or acquisition-related equity issuance
- Modest ROE of 10.4% and ROA of 7.8% lag expectations for such high-margin business, indicating potential asset inefficiency or recent capital deployment
- Capital-intensive medical device industry may require sustained CapEx (currently $260M) limiting future cash return flexibility
- 11 Form 4 insider filings in 90 days without directional context could indicate uncertainty or routine executive trading patterns
Key Metrics to Watch
- Organic revenue growth rate normalized for one-time items (current 29,843% YoY clearly anomalous)
- Share dilution trends and acquisition-related charges impacting EPS accretion going forward
- Operating cash flow sustainability and working capital efficiency (currently $1.6B OCF)
- Return on equity trajectory toward industry benchmarks as capital integration matures
- Capital expenditure as percentage of revenue and free cash flow yield to shareholders
EW Financial Metrics
EW Profitability Ratios
EW Balance Sheet & Liquidity
EW 5-Year Financial Trend
5-Year Trend Summary: Edwards Lifesciences Corp's revenue has grown significantly by 16% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.30 reflects profitable operations.
EW Growth Metrics (YoY)
EW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4B | $291.1M | $0.50 |
| Q2 2025 | $1.4B | $333.2M | $0.56 |
| Q1 2025 | $1.3B | $351.9M | $0.58 |
| Q3 2024 | $1.2B | $384.9M | $0.63 |
| Q2 2024 | $1.3B | $307.1M | $0.50 |
| Q1 2024 | $1.5B | $340.5M | $0.56 |
| Q3 2023 | $1.3B | $343.5M | $0.55 |
| Q2 2023 | $1.4B | $307.1M | $0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EW Capital Allocation
EW SEC Filings
Access official SEC EDGAR filings for Edwards Lifesciences Corp (CIK: 0001099800)